45 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22709 | 4 lines chemotherapy and radiation | Bogdan Grigoriu | Lung | AstraZeneca | ADRIATIC | Trial closed for recruitment | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) | Bogdan.Grigoriu@hubruxelles.be | 3 | 3 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22732 | Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation | Nuria Kotecki | Multiple | Amgen | AMG510 | Trial closed for recruitment | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation | Nuria.Kotecki@hubruxelles.be | 1/2 | 1 | |
| 22718 | Ongoing problemn with apetite/eating. Maximum 3 lines of systemic prior | Thierry Berghmans | NSCLC | Helsinn Healthcare SA | ANAM-17-21 | Trial closed | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced nonsmall cell lung cancer (NSCLC) | 3 | 3 | ||
| 22652 | EGFR activating mutation associated with EGFR-TKI sensitivity | Thierry Berghmans | Lung | EORTC | Apple | Trial closed | APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients | 3 | 3 | ||
| 29048 | Mariana Brandao | Lung | AstraZeneca | ARTEMIDE-01 | Trial open for recruitment | A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01)(D7020C00001) | mariana.brandao@hubruxelles.be | 1/2 | 1 | ||
| 22613 | Nodule 5-20 mm of undetermined nature in at least one lung. | Thierry Berghmans | Lung | European Lung Cancer Working Party | B079201215796 | Trial open for recruitment | Role of bronchoscopy assisted by electromagnetic navigation (EMN) in the diagnosis of small pulmonary nodules of indeterminate nature. A prospective study by the European Lung Cancer Working Party | 2 | 2 | ||
| 22621 | Lung cancer No prior treatment |
Anne-Pascale Meert | Lung | European Lung Cancer Working Party | B079201523324 | Trial closed for recruitment | Does inflammation have a significant implication in Lung Cancer evolution? | ap.meert@hubruxelles.be | |||
| 28640 | RET-fusion | Thierry Berghmans | Lung | Blueprint Medicines Corporation | BLU-667-2303 | Trial closed | A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer | 3 | 3 | ||
| 22651 | Metastatic | Christiane Jungels | Multiple | Cantargia AB | CANFOUR | Trial closed | An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors | christiane.jungels@hubruxelles.be | 1/2 | 1 | |
| 29061 | Bogdan Grigoriu | Lung | Novartis | CANOPY-N | Trial closed | A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N) | Bogdan.Grigoriu@hubruxelles.be | 2 | 2 | ||
| 29646 | Thierry Berghmans | Lung | Inhatarget Therapeutics | CIS-DPI-01 | Trial open for recruitment | A Phase I/IIa First-in-Human Single-arm Open-label Multicentre Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Cisplatin-based Formulation Administered as Dry Powder for Inhalation in Combination with First Line Standard of Care in Patients with Stage IV Non-Small Cell Lung Cancer (CIS-DPI-01) | 1/2a | 1 | |||
| 22824 | Anaplasic lymphoma kinase (ALK) positive | Thierry Berghmans | Multiple | Novartis | CLDK378A2303 | Trial closed | A Phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib | 3 | 3 |